Safety and Efficacy of Mavacamten and Aficamten in Patients With Hypertrophic Cardiomyopathy.

ABSTRACT:

Background

Cardiac myosin inhibitors were recently developed to address the underlying pathophysiology of hypertrophic cardiomyopathy and to improve symptoms and quality of life. In this review, we evaluated the pharmacologic profile and clinical outcomes for mavacamten and aficamten, 2 cardiac myosin inhibitors investigated in symptomatic hypertrophic cardiomyopathy.

Methods and results

Using a systematic search, 10 clinical trials with safety and efficacy data for either drug in obstructive hypertrophic cardiomyopathy (oHCM) and nonobstructive hypertrophic cardiomyopathy were included. Additionally, we included data from regulatory agencies. Both drugs demonstrated substantial benefit in reducing left ventricular outflow tract obstruction (Valsalva left ventricular outflow

SUBMITTER: Davis BJ 

PROVIDER: S-EPMC12132771 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature